BR0109193A - Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma - Google Patents

Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma

Info

Publication number
BR0109193A
BR0109193A BR0109193-0A BR0109193A BR0109193A BR 0109193 A BR0109193 A BR 0109193A BR 0109193 A BR0109193 A BR 0109193A BR 0109193 A BR0109193 A BR 0109193A
Authority
BR
Brazil
Prior art keywords
agonist activity
glaucoma
treatment
ht1a agonist
activity compounds
Prior art date
Application number
BR0109193-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert J Collier Jr
Thomas R Dean
Mark R Hellberg
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0109193A publication Critical patent/BR0109193A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
BR0109193-0A 2000-03-17 2001-02-20 Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma BR0109193A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
PCT/US2001/005432 WO2001070223A1 (en) 2000-03-17 2001-02-20 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma

Publications (1)

Publication Number Publication Date
BR0109193A true BR0109193A (pt) 2003-05-27

Family

ID=22700682

Family Applications (3)

Application Number Title Priority Date Filing Date
BR0109193-0A BR0109193A (pt) 2000-03-17 2001-02-20 Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma
BR0109230-8A BR0109230A (pt) 2000-03-17 2001-02-23 Compostos com atividade 5-ht, úteis para controle da perda do campo visual
BR0109211-1A BR0109211A (pt) 2000-03-17 2001-02-23 Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR0109230-8A BR0109230A (pt) 2000-03-17 2001-02-23 Compostos com atividade 5-ht, úteis para controle da perda do campo visual
BR0109211-1A BR0109211A (pt) 2000-03-17 2001-02-23 Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa

Country Status (18)

Country Link
EP (3) EP1263434A1 (enExample)
JP (5) JP2003527423A (enExample)
KR (3) KR20030016239A (enExample)
CN (2) CN1198605C (enExample)
AR (1) AR028258A1 (enExample)
AT (1) ATE247507T1 (enExample)
AU (5) AU2001238552A1 (enExample)
BR (3) BR0109193A (enExample)
CA (3) CA2400637A1 (enExample)
DE (1) DE60100625T2 (enExample)
DK (1) DK1263504T3 (enExample)
ES (1) ES2204848T3 (enExample)
MX (3) MXPA02009071A (enExample)
PL (1) PL203709B1 (enExample)
PT (1) PT1263504E (enExample)
TW (1) TWI268777B (enExample)
WO (3) WO2001070223A1 (enExample)
ZA (1) ZA200206350B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
JP2003527423A (ja) * 2000-03-17 2003-09-16 アルコン、インコーポレイテッド 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
HUE040019T2 (hu) 2009-11-09 2019-02-28 Allergan Inc Hajnövekedést stimuláló készítmények és módszerek
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
JP6511401B2 (ja) 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続型薬物送達インプラント
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
SG11202109111VA (en) 2019-02-27 2021-09-29 Univ California Azepino-indoles and other heterocycles for treating brain disorders
SG11202109020QA (en) 2019-02-27 2021-09-29 Univ California N-substituted indoles and other heterocycles for treating brain disorders
MX2024007221A (es) 2021-12-15 2024-08-27 Delix Therapeutics Inc Psicoplastogenos sustituidos con fenoxi y benciloxi y sus usos.
ES3030316T3 (en) * 2021-12-23 2025-06-27 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
JP2003527423A (ja) * 2000-03-17 2003-09-16 アルコン、インコーポレイテッド 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物

Also Published As

Publication number Publication date
AU2001239836A1 (en) 2001-10-03
KR20020082885A (ko) 2002-10-31
PL203709B1 (pl) 2009-11-30
WO2001070222A2 (en) 2001-09-27
CN1418100A (zh) 2003-05-14
CN1198605C (zh) 2005-04-27
KR20030016239A (ko) 2003-02-26
DK1263504T3 (da) 2003-12-08
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
WO2001070230A3 (en) 2002-04-25
MXPA02009073A (es) 2003-03-12
JP2003527427A (ja) 2003-09-16
TWI268777B (en) 2006-12-21
PT1263504E (pt) 2003-12-31
KR100749191B1 (ko) 2007-08-13
DE60100625D1 (de) 2003-09-25
JP2011153158A (ja) 2011-08-11
WO2001070223A1 (en) 2001-09-27
MXPA02009071A (es) 2003-05-23
CA2399985A1 (en) 2001-09-27
EP1263504A2 (en) 2002-12-11
PL358306A1 (en) 2004-08-09
JP2011037901A (ja) 2011-02-24
ZA200206350B (en) 2003-08-08
AR028258A1 (es) 2003-04-30
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
JP2003527423A (ja) 2003-09-16
CN1418121A (zh) 2003-05-14
ES2204848T3 (es) 2004-05-01
JP2003527422A (ja) 2003-09-16
WO2001070222A3 (en) 2002-07-25
EP1263434A1 (en) 2002-12-11
AU2005202600B2 (en) 2008-07-31
HK1051504A1 (en) 2003-08-08
EP1267878A2 (en) 2003-01-02
EP1263504B1 (en) 2003-08-20
ATE247507T1 (de) 2003-09-15
DE60100625T2 (de) 2004-02-26
CA2400639C (en) 2011-08-16
MXPA02009072A (es) 2003-03-12
WO2001070230A2 (en) 2001-09-27
AU4531001A (en) 2001-10-03
CA2400637A1 (en) 2001-09-27
KR20030009390A (ko) 2003-01-29
CA2400639A1 (en) 2001-09-27
BR0109230A (pt) 2003-06-03
JP4789231B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
BR0109193A (pt) Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
BR9813684A (pt) Processo para tratar o glaucoma glc1a, e, composição para controlar o glaucoma glc1a.
SE9903998D0 (sv) New compounds
PT1204654E (pt) Benzofurilpiperazinas agonistas do receptor 5-ht2c da serotonina
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
GB0225474D0 (en) Therapeutic agents
PT845991E (pt) Utilizacao de difosfonatos substituidos com fenol como agentes anti-neoplasicos
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
FI922785A0 (fi) Terapeutiska preparat.
MY134110A (en) Combinations of reboxetine and neuroleptic agents
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
DE69708968D1 (de) Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
DK0960111T3 (da) Morphinderivat med analgesisk aktivitet
TR200400424T4 (tr) IOP'nin kontrolü ve glokom tedavisi için 5HT2 agonistleri
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DE69703796D1 (de) N-bis- oder n-tris-[(1,2-dicarboxy-ethoxy)-ethyl]-amin-derivate und herstellung und anwendung derselben
BR0017168A (pt) Piranoindóis para tratamento de glaucoma
ES2182509T3 (es) Derivados de n-ariloxietilamina para el tratamiento de la depresion.
WO2003051291A3 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
ATE279925T1 (de) Verwendung von halofuginon zur herstellung eines medikaments zur vorbeugung von neovaskularisation und zur behandlung bösartiger tumore
ATE232723T1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]